Lupin pharma


Posted On Sep 18 2016 by

#lupin pharma

#

With our feet firmly planted in today, we envision a bigger,
brighter tomorrow..That is what we are here for.
For Tomorrow

We remain committed to innovate; to deliver affordable &
quality medicines to customers globally. Quality Formulations
for everyone.
For Tomorrow

With our feet firmly planted in today, we envision a bigger,
brighter tomorrow..That is what we are here for.
For Tomorrow

At Lupin there are no shortcuts to Quality; Manufacturing
medicines is a responsibility and an obligation that we have
to communities we serve.
For Tomorrow

Lupin Receives Tentative Approval for Generic Zithromax Oral Suspension

Pharma Major Lupin Limited announced today that its US subsidiary, Gavis Pharmaceuticals LLC. U.S.A. (collectively Lupin) has received tentative approval for its Azithromycin for oral suspension USP, 300 mg (100 mg/5 mL) and 1200 mg (200 mg/5 mL) from the United States Food and Drug Administration (FDA).

Lupin Receives Tentative Approval for Generic Paxil CR Tablets

Pharma Major Lupin Limited (Lupin) announced today that it has received tentative approval for its Paroxetine Extended-Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg from the United States Food and Drug Administration (FDA) to market a generic version of Apotex Technologies, Inc.’s Paxil CR® Tablets, 12.5 mg, 25 mg and 37.5 mg.

Lupin Receives FDA Approval for Generic Zyvox Tablets

Pharma Major Lupin Limited announced today that its US subsidiary, Gavis Pharmaceuticals LLC. U.S.A. (collectively Lupin) has received final approval for its Linezolid Tablets, 600 mg from the United States Food and Drug Administration (FDA) to market a generic equivalent of Pharmacia & Upjohn Company’s Zyvox® Tablets, 600 mg.


Last Updated on: September 18th, 2016 at 12:49 am, by


Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *